Xilio Therapeutics (XLO)

• Market cap: $50M
• 1 day: -5.11%
• 5 days: 5.69%
• 1 month: -0.48%
• 3 months: 7.18%
• 6 months: -17.55%
• Year to date: -11.06%
• 1 year: -25.36%
• 5 years: -96.27%
• 10 years: -96.27%
• Sector: Healthcare
• Industry: Biotechnology

About: Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.

Employees: 76